Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva versus placebo in advanced non-small cell lung cancer unsuitable for chemotherapy
ISRCTN77383050Phase 3Completed
- Sponsor
- University College London
- Start
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tarceva with Matched placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN77383050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77383050.